Pooled evidence from 2 randomized trials and 6 observational cohorts suggests posttransplant gilteritinib maintenance may ...
Tyrosine kinase inhibitors (TKIs) lead to similar outcomes across racial and ethnic groups when used to treat acute myeloid ...
In PV and ET, MDS risk remains lower than AML risk but increases progressively with advancing attained age. Transformation to acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in ...
The panel reached ≥97.8% consensus on AML management. The panel agreed to use international risk stratification categories for personalized treatment of AML. The presence of ≥10% blasts for recurrent ...
Stocktwits on MSN
SLS stock pops after-hours as loss shrinks, cash swells — all eyes on high stakes AML trial in 'pivotal' 2026
Net loss in FY25 narrowed to $26.9 million from $30.9 million a year ago, with R&D costs falling to $16 million. ・Phase 3 ...
Although survival rates for acute myeloid leukemia (AML) continue to improve, many long-term survivors face persistent ...
The therapeutic arsenal for the management of AML has expanded significantly in recent years. Before 2017, newly diagnosed AML was treated with either standard cytarabine- and anthracycline-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results